Healthcare Industry News: GTx
News Release - September 18, 2007
Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive OfficerLONDON, Sept. 18 (HSMN NewsFeed) -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that it has appointed Rosemary Mazanet M.D., Ph.D. as its interim Chief Executive Officer. Dr. Mazanet has significant experience in both executive and operational management in the biopharmaceutical industry.
Dr. Mazanet serves on the Board of numerous private and public pharmaceutical companies. From June 1998 to February 2004, Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners, L.P., a healthcare investment firm. As Senior Director of Clinical Research at Amgen in the early and mid 1990s, she was responsible for the submission of corporate INDs, the registration strategy and conduct of Phase I, II and III clinical trials. Dr. Mazanet also serves as an independent director at GTx, Inc. (Nasdaq: GTxI ) and is a trustee at the University of Pennsylvania, School of Medicine where she received her M.D. and Ph.D. Dr. Mazanet was trained as an oncologist in the Harvard Medical System where she was also a faculty member.
Dr. Mazanet commented, "I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation," said Dr. Mazanet. "We believe this new family of Multifunctional Anti-Inflammatory Drugs (MFAIDS) could bring significant benefits to patients with many different inflammatory conditions including skin, respiratory and gastrointestinal indications."
"Dr. Mazanet has a strong track record in operations, finance and regulatory affairs. We are very fortunate to have attracted the caliber of management as strong as Dr. Mazanet as Morria enters a new stage in its clinical development," said Mark Cohen, Chairman of the Board of Morria.
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of novel anti-inflammatory pharmaceuticals termed Multi- Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, pulmonary and gastro-intestinal inflammatory diseases. For more information please visit http://www.morria.com.
This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.
Source: Morria Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.